Esfahani Ali, Ghoreishi Zohreh, Nikanfar Alireza, Sanaat Zohreh, Ghorbanihaghjo Amir
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Iran.
Acta Med Iran. 2012;50(7):454-8.
Chemotherapeutic agents used in patients with cancer cause to generate the enormous amounts of free radicals associated with cell injury. In this study we assess the effects of chemotherapy regimen on oxidant/antioxidant status in patients with acute myeloid leukemia (AML). 38 newly diagnosed patients with acute myeloid leukemia were recruited in this study. All patients received cytarabine and daunorubicin as chemotherapy regimen. Plasma levels of malondialdehyde (MDA), total antioxidant status (TAS), and the levels of erythrocyte activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx) were determined before chemotherapy and 14 days after chemotherapy with cytarabine and daunorubicin. Plasma MDA concentrations increased significantly (from 2.68 ± 0.89 nmol/L to 3.14 ± 1.29 nmol/L) during the 14 days post-chemotherapy period (P=0.04). Plasma TAS concentrations changed with chemotherapy from 1.09 ± 0.15 mmol/L to 1.02 ± 0.14 mmol/L with P=0.005. Erythrocyte SOD and GPX activity decreased overtime from 1157.24 ± 543.61 U/g Hb to 984.01 ± 419.09 U/g Hb (P=0.04) and 46.96 ± 13.70 U/g Hb to 41.40 ± 6.44 U/g Hb (P=0.02) respectively. We report here that there is an increase in malondialdehyde levels and a decrease in the levels of antioxidant enzymes and total antioxidant status. This suggests that chemotherapy causes these changes as a result of enormous production of reactive oxygen species in the patients with AML. Antioxidant supplementation must be approached with caution because of the probability of reduction the therapeutic efficacy of these cytotoxic drugs.
用于癌症患者的化疗药物会导致产生与细胞损伤相关的大量自由基。在本研究中，我们评估了化疗方案对急性髓系白血病（AML）患者氧化/抗氧化状态的影响。本研究招募了38例新诊断的急性髓系白血病患者。所有患者均接受阿糖胞苷和柔红霉素作为化疗方案。在化疗前以及使用阿糖胞苷和柔红霉素化疗14天后，测定血浆丙二醛（MDA）水平、总抗氧化状态（TAS）以及红细胞超氧化物歧化酶（SOD）和谷胱甘肽过氧化物酶（GPx）的活性水平。化疗后14天内，血浆MDA浓度显著升高（从2.68±0.89 nmol/L升至3.14±1.29 nmol/L）（P = 0.04）。化疗后血浆TAS浓度从1.09±0.15 mmol/L变为1.02±0.14 mmol/L，P = 0.005。随着时间推移，红细胞SOD和GPX活性分别从1157.24±543.61 U/g Hb降至984.01±419.09 U/g Hb（P = 0.04）以及从46.96±13.70 U/g Hb降至41.40±6.44 U/g Hb（P = 0.02）。我们在此报告，丙二醛水平升高，抗氧化酶水平和总抗氧化状态降低。这表明化疗导致这些变化是由于AML患者体内大量产生活性氧所致。由于补充抗氧化剂可能会降低这些细胞毒性药物的治疗效果，因此必须谨慎对待。
